Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$55.38M+144.55%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian Goff
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 540
- Beta
- 0.62
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 10.31
Financials
Revenue
$55.38M+144.5%Net Income
$-65.05MEBITDA
$-63.59MFree Cash Flow
$-60.42MEPS (diluted)
$-1.09Shares Outstanding (diluted)
59.71M+41.8%Operating Expenses
$130.02MCash & Debt
$630.01MReturn of Capital
$0.00Revenue by Segment (annual)
$54.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.03M | $-412.78M | $-7.12 |
| 2024 | $36.50M | $673.73M | $11.86 |
| 2023 | $26.82M | $-352.09M | $-6.33 |
| 2022 | $14.24M | $-231.80M | $-4.23 |
| 2021 | $0.00 | $1.60B | $-6.36 |
| 2020 | $0.00 | $-327.37M | $-4.74 |
| 2019 | $117.91M | $-411.47M | $-6.61 |
| 2018 | $94.39M | $-346.03M | $-6.03 |
| 2017 | $43.01M | $-314.67M | $-6.75 |
| 2016 | $69.89M | $-198.47M | $-5.07 |
| 2015 | $59.12M | $-117.73M | $-3.15 |
| 2014 | $65.36M | $-53.50M | $-1.59 |
| 2013 | $25.55M | $-39.41M | $-2.56 |
| 2012 | $25.11M | $-20.10M | $-0.86 |
Valuation
AGIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-12.50%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·15d ago·Positive
Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Alec Stranahan - BofA Securities, Research Division Sama…
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call Agios Pharmaceuticals NASDAQ: AGIO reported record third-quarter product revenue as its thalassemia drug AQVESME continued its U.S. launch, while the company prepares for a delayed regulatory decision on the drug's use in sickle cell disease.
View source ↗ - Newszacks.com·17d ago·Neutral
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…s and pipeline programs; company is targeting non-GAAP profitability in 2028 CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2026.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade) Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. Mitapivat's efficacy in SCD is mixed—endpoint for pain crises not met, but strong reductions in transfusion burden demonstrated. The FDA's delay centers on safety and REMS considerations, not efficacy; no new hepatocellular injury cases were reported in updated safety data.
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
…A as part of the ongoing sNDA review, including elements of a potential REMS CAMBRIDGE, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for mitapivat, an oral pyr…
View source ↗ - Newszacks.com·24d ago·Neutral
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m.
View source ↗ - Newszacks.com·47d ago·Positive
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
View source ↗ - Newszacks.com·51d ago·Positive
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $-1.09 per share
Typical surprise +6.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-1.09 vs $-1.24beat
- Thu, Jul 30$-1.69 vs $-1.65miss
- Wed, Apr 29$-1.69 vs $-1.81beat
- Thu, Feb 12$-1.85 vs $-1.97beat
- Thu, Oct 30$-1.78 vs $-1.93beat
- Thu, Jul 31$-1.93 vs $-1.74miss
Estimates and results for AGIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AGIO officers and directors.
- Bought
- —
- Sold
- $3.4m
0 trades
17 trades
- Gheuens Sarahsold
- Gheuens Sarahsold
- Gheuens Sarahsold
- Gheuens Sarahsold
- Gheuens Sarahsold
- Burns James Williamsold
- Gheuens Sarahsold
- Jones Ceciliasold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (22d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (32d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 7, 2025 (20d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 12, 2025 (14d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (22d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
